Latham & Watkins Advises on Windward Bio’s IPO

Windward Bio Group AG (Windward) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, has announced the pricing of its initial public offering of 10,294,117 common shares at a public offering price of US$17 per share. In addition, Windward has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 common shares at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to Windward from the initial public offering and the concurrent private placement, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, are expected to be US$225 million. All of the common shares are being offered by Windward.

Latham & Watkins LLP advised the underwriters in the transaction with a Capital Markets team led by New York partners Nathan Ajiashvili and Kaj Nielsen, with associates Jie Lin Nai, Elana Cates, and Renad AlQarni.*

*Admitted to practice in Saudi Arabia only.